A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Balversa
(Canada) [Available]Synonyms :
Class :
Anticancer & protein kinase inhibitors
Brand Name :
Balversa
(Canada) [Available]Synonyms :
Class :
Anticancer & protein kinase inhibitors
Dosage Forms & StrengthsÂ
Tablet, OralÂ
3 mgÂ
4 mgÂ
5 mgÂ
Note: Serum phosphate level assessment should be done after 14 to 21 days after therapy initiation; if a dose is missed administer the dose on the same day; if the dose is vomited, continue with the next dose on the next day, do not administer an extra dose to make up.
Initial:
8
mg
oral
once a day
Dose Adjustments
After 14 to 21 days: 9 mg oral once a day (if serum phosphate < 5.5 mg/dl and no ocular disorder).
No safe and efficacious dosage is availableÂ
Refer to adult dosingÂ
erdafitinib: they may diminish the serum concentration of CYP3A4 Inducers
erdafitinib: they may diminish the serum concentration of CYP3A4 Inducers
erdafitinib: they may diminish the serum concentration of antacids
erdafitinib: they may diminish the serum concentration of antacids
erdafitinib: they may diminish the serum concentration of antacids
erdafitinib: they may diminish the serum concentration of antacids
erdafitinib: they may diminish the serum concentration of antacids
may decrease the therapeutic effect
may enhance the serum concentration of CYP2C9 inhibitors
may decrease the therapeutic effect of serum phosphate level-altering agents
may enhance the serum concentration of OCT2 substrates
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
nafcillin will decrease the effect of action of erdafitinib by affecting enzyme CYP3A4 metabolism.
may enhance the immunosuppressive effect of immunosuppressants
when both drugs are combined, there may be an increased metabolism of erdafitinib   
on interacting with brentuximab vedotin, erdafitinib will increase the effect of brentuximab.
increases serum level of daunorubicin by P-glycoprotein efflux transporter
the effect of erdafitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
erdafitinib increases the effect of lapatinib with the help of P-glycoprotein MDR1 efflux transporter
CYP3A strong enhancers of the small intestine may reduce the bioavailability of erdafitinib
increases serum level of idarubicin by P-glycoprotein efflux transporter
it increases the effect of sitagliptin via the MDR1 efflux transporter
it increases the effect of linagliptin via the MDR1 efflux transporter
it decreases the concentration of CYP3A4 substrates in serum
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may diminish the serum concentration of CYP3A4 Substrates
the interaction may enhance the hypertensive effect
the interaction with erdafitinib may increase the risk of hemorrhage in patients with low platelets count
the interaction may increase the active metabolite serum concentration of artesunate
erdafitinib may increase the cardiotoxic and hepatotoxic effects of avelumab
the interaction with erdafitinib may enhance the risk of osteonecrosis
May decrease the serum level of erdafitinib by affecting the enzyme CYP3A4
cimetidine may enhance the level and effect of erdafitinib by affecting CYP3A4
may increase the serum level of CYP3A4 substrates
may enhance serum level or toxic effect by affecting MDR1/PG-P efflux transporter
decrease the serum level of erdafitinib by affecting CYP3A4
may enhance serum levels of erdafitinib by affecting the MDR1/PG-P efflux transporter
may reduce therapeutic effects of erdafitinib by inducing hepatic metabolism enzyme CYP3A4
may enhance the serum levels of CYP3A4 substrates
may enhance the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may reduce the effects of erdafitinib by affecting the MDR1/PG-P efflux transporter
may reduce serum levels of erdafitinib by affecting MDR1/PG-P efflux transporter
may increase the serum concentration of erdafitinib
may reduce intracellular concentration by affecting the MDR1/Pg-P efflux transporter
erdafitinib may increase the hepatotoxic effects of pembrolizumab
may increase the hypertension effects of solriamfetol erda
may increase the serum concentration of erdafitinib
may increase the serum concentration of erdafitinib
may decrease the serum concentration of erdafitinib.
may decrease the serum concentration of erdafitinib.
may decrease the serum concentration of erdafitinib.
may decrease the serum concentration of erdafitinib.
may decrease the serum concentration of erdafitinib.
When erdafitinib is used together with ridaforolimus, this leads to enhanced concentration serum of erdafitinib
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased metabolism of erdafitinib 
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration  
may increase the serum concentration of tamoxifen
may reduce the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
it may reduce the plasma concentration of CYP3A4 substrates
the CYP3A4 substrate serum concentration is increased by erdafitinib
it increases the concentration of CYP3A4 substrates in serum
may reduce the serum concentration of CYP3A4 substrates
it may increase or decrease the concentration of CYP3A4 substrates in serum
it increases the concentration of CYP3A4 substrates in serum
it increases the concentration of CYP3A4 substrates in serum
it increases the concentration of P-Glycoprotein or ABCB1 substrates in serum
it decreases the concentration of CYP3A4 substrates in serum
it increases the concentration of CYP3A4 substrates
May enhance the plasma concentration of CYP3A4 substrates
may increase the arrhythmogenic effect of Inhalational Anaesthetics
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
A transmembrane protein called fibroblast growth factor receptor (FGFR) is widely expressed in healthy tissues and has a role in several endogenous bio-physiological functions.Â
Oral selective pan-FGFR kinase inhibitor erefitinib binds to and inhibits the enzymatic activity of expressed FGFR1, FGFR2, FGFR3, and FGFR4, according to in vitro findings. Â
Frequency defined:Â
>20-10%Â
Increased serum potassium (16%)Â
Decreased serum sodium (40%)Â
Fatigue (54%)Â
Abdominal pain (24%)Â
Constipation (25%)Â
Dyspepsia (19%)Â
Stomatitis (29%)Â
Skin rash (35%)Â
Peripheral edema (35%)Â
Dehydration (12%)Â
Hyperuricemia (16%)Â
Hypoalbuminemia (14%)Â
1-10%Â
Atrial fibrillation (8%)Â
Cardiac failure (2%)Â
Weight loss (10%)Â
Gastrointestinal hemorrhage (4%)Â Â
Postmarketing:Â Â
Acute hepatic failureÂ
Hepatic cirrhosisÂ
Hepatic failureÂ
Anaphylactic shockÂ
Renal failure syndromeÂ
Â
None
Contraindication:Â
NoneÂ
Caution:Â
Ocular disordersÂ
HyperphosphatemiaÂ
Pregnancy consideration: erdafitinib is assigned under pregnancy category C based on animal studies.Â
Lactation: No data available for excretion in breast milk, it should be avoided due to potential side effects. Â
Pregnancy category:Â
For early cycles, continuous daily dosing of erefitinib should be increased to the maximum indicated dose to reach target blood phosphate levels of 5.5–7.0 mg/dL.Â
Before the first erdafitinib dose increase period based on serum phosphate levels, concurrent use of medicines that can change serum phosphate levels was also avoided.Â
When erdafitinib was administered, it was found to raise serum phosphate levels due to FGFR inhibition.
It is administered through oral route in form of tablet.Â
It should be taken with or without food.Â
Swallow tablets whole at time and avoid chewing or crush.Â
The next dose of erdafitinib should be taken the day after if vomiting occurs at any point after taking it.Â
Patient Information Leaflet  Â
Generic Name: erdafitinib (Rx)  Â
Pronounced:Â
Why do we use erdafitinib?Â
A pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor called erefitinib is prescribed to treat adult patients with metastatic or locally advanced urothelial cancer.Â
The FDA has granted expedited approval for the aforementioned indication based on tumor response rate. Confirmatory trials may be required to verify and describe the clinical benefit before this indication can continue to be approved.Â
Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
